Thrombocytopenia Treatment Market Size, Share, Outlook, and Opportunity Analysis 2018–2026

Thrombocytopenia Treatment Market

                    Thrombocytopenia Treatment Market




Thrombocytopenia is an auto immune haematological bleeding condition characterised by a lack of platelets in the blood vessels. To overcome thrombocytopenia, the platelet count must be regularly maintained at a safe range. Thrombocytopenia can develop in people with a platelet count of fewer than 100,000 platelets/L owing to a decrease in megakaryocytes in the bone marrow, drugs that destroy platelets, and immunological diseases.


Blood in the urine, headaches, heavy menstrual periods, skin patches, and bruises are all symptoms of thrombocytopenia. Cancer treatments, such as chemotherapy and drug-induced medicines, as well as radiation therapy, can cause thrombocytopenia.


The global incidence of thrombocytopenia is driving the thrombocytopenia treatment market. Chronic Hepatitis C patients are at a substantially increased risk of developing thrombocytopenia. According to the World Health Organization (WHO), in 2014, the prevalence of Hepatitis C in the Americas and Europe was lower than in Africa and Pakistan, where the incidence of chronic liver disease was 4-6 percent greater than in the Americas and Europe. Because 60-80 percent of the population suffers liver disease, it has become a socioeconomic and worldwide health issue.


Additionally, rising government support for fast-track approval in order to discover newer treatments for this disorder, as well as increased investment in the development of new drugs by biotechnology and pharmaceutical companies, are expected to drive the thrombocytopenia treatment market forward during the forecast period. However, due to patent expiry and the rising availability of generic versions of Promacta and MabThera, the thrombocytopenia treatment market is expected to slow significantly from 2023.


Market Segmentation:

By Drug Class:
  • Glucocorticoids
  • Lysosomal Enzyme
  • Platelet Stimulating Agent


By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

The major key players in thrombocytopenia treatment market include 3SBio Inc., Amarillo Biosciences, Inc., Amgen Inc., Baxalta Incorporated, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cellerant Therapeutics, Inc., Eisai Co., Ltd., Hansa Medical AB, Intas Pharmaceuticals Ltd., Merck & Co., Inc., Momenta Pharmaceuticals, Inc., Myelo Therapeutics GmbH, Neumedicines Inc., Novartis AG, Pfizer Inc., Prophylix Pharma AS, Rigel Pharmaceuticals, Inc., Shionogi & Co., Ltd., STATegics, Inc., and ViroMed Co., Ltd.

Comments

Popular posts from this blog

Molecular Sieves Catalyst Market: Global Company Analysis and Forecast 2018 – 2026 | Albemarle Corporation, W. R. Grace and Company, Silkem Ltd., Sinopec Group, and JGC Catalysts & Chemicals Ltd.

Biolubricants Market Size, Share, Growth, Opportunities, Global Analysis and Opportunity Assessment 2019 – 2027

Shared Services Market by Function, By Number of Services and By Region – Global Opportunities & Forecast 2019 - 2027